Skip to main content
. Author manuscript; available in PMC: 2013 Apr 8.
Published in final edited form as: Cell Cycle. 2009 Jul 23;8(14):2266–2280. doi: 10.4161/cc.8.14.9101

Figure 4.

Figure 4

VEGFR-3 increases viability of breast cancer cells. (A) MTS assay (24 h) of MCF7-VEGFR-3 and MCF7-pcDNA3 cells. Viability was normalized relative to MCF7-pcDNA. (B) BT474 cells viability measured 24 h after pretreatment for 48 h with 10 nM VEGFR-3-specific and Control siRNAs. Viability normalized relative to untreated BT474 cells. (C) Viability of MCF7-VEGFR-3 cells in comparison to clones with VEGFR-3 shRNA knockdown, normalized relative to parental clone. (D) Viability of BT474 cells in comparison to clones with VEGFR-3 shRNA knockdown, normalized relative to parental clone.